A commercialisation workshop, a sold-out symposium, and new milestones from our resident startups — it has been another productive period at Jumar Bioincubator in Melbourne.
As Australia’s first biotech incubator co-located with a global biopharmaceutical company, Jumar continues to support early-stage biotech startups, researchers, and founders as they translate scientific discoveries into real-world impact. Here’s a look at what’s been happening across our community.
We wrapped up BioElevate, Jumar's two-day commercialisation workshop
We recently wrapped up the latest cohort of BioElevate, Jumar’s two-day biotech commercialisation workshop designed to help research teams take their first steps toward building a startup.
Across two intensive days, participants worked through:
- Identifying and articulating unmet clinical needs
- Validating ideas through customer discovery
- Exploring biotech funding pathways
- Understanding what it takes to build a sustainable biotech venture
The program concluded with a closed-door pitch session, where teams presented to venture capital investors and tested their ideas in a real-world setting.
One participant captured the experience well:
“It was two days of a lot of information all aimed to prepare us for the future in the commercial world. My brain worked hard and I loved every minute of it."
BioElevate is part of Jumar’s broader mission to support biotech startup development and research commercialisation in Australia. Expressions of interest for next year’s cohort will open soon. Interested in joining next year's cohort? Learn more about Bioelevate and submit an EOI here.
We sold-out our pre-clinical to commercial symposium
In collaboration with the Monash Institute of Pharmaceutical Sciences, Jumar hosted the Pre-Clinical to Commercial Symposium in Melbourne, bringing together more than 100 attendees from across the biotech ecosystem.
The event explored the full pathway from early-stage discovery through to clinical development and commercialisation, with insights from researchers, academics, biotech startups, and industry leaders.
Takeaways included:
- 🧪 Start early, build strong foundations
CMC begins in preclinical, not later. Early decisions on manufacturability, stability, and quality shape everything that follows.
- 🔍 Know your asset deeply
From physicochemical characterisation to stress testing, understanding your molecule is key to linking research with clinical outcomes.
- 📋 Regulatory strategy isn’t optional
Early alignment, clear Target Product Profiles, and proactive engagement with regulators are critical.
- ⚖️ Balance speed, risk, and data
Startups highlighted the challenge of moving fast while generating meaningful, patient-relevant evidence, all under capital constraints.
- 💼 Think commercial from day one
Partnering, market alignment, and investment readiness are essential to crossing the “valley of death”.
- 🤝 Collaboration drives progress
Bringing together researchers, startups, and industry is key to accelerating translation.
We thank our speakers, attendees, and sponsors — City of Melbourne, Charles River Laboratories, Proteintech, Eurofins Australia, and SCHOTT Pharma — for contributing to a highly valuable day for the Australian biotech ecosystem.
We continue to build a strong biotech community in Melbourne
At Jumar, community is central to everything we do. Our monthly community events provide an opportunity for residents to step away from the lab, connect with peers, and share experiences.
With more than 30 biotech ventures spanning therapeutics, vaccines, diagnostics, medtech, and gene and cell therapies, these moments help foster collaboration across disciplines.
Jumar is more than a lab space — it is a connected ecosystem supporting innovation, knowledge exchange, and company growth.
Resident biotech startup highlights
Our resident companies continue to achieve important milestones across research, partnerships, and clinical development:
- Celleo announced its first customer delivery of the Larkem® V40, a closed, automated vial filling system for cell therapy production.
- 121SEED joined a 5-year $1.48M ARC Linkage Project focused on improving wheat and soybean outcomes for the Australian agrifood sector.
- Denteric commenced a Phase 1 clinical trial for its first-in-class investigational therapy targeting Alzheimer’s disease.
- Immunosis partnered with Intergen Genetics to advance RNA-based diagnostic technology for immune dysregulation.
Learn more about our residents and the amazing work they do here.
Looking for lab or office space for your biotech startup?
Jumar Bioincubator provides flexible lab and office space designed for biotech startups at every stage of growth. Our facilities include:
- Rent-a-bench options
- Co-working desks
- Private offices
- PC2 laboratories
- Access to specialised equipment
Located in the Melbourne Biomedical Precinct, Jumar offers not only infrastructure but also a supportive community and access to industry networks, investors, and commercialisation programs.
If you are building a biotech company and looking for lab space in Melbourne, we invite you to get in touch with the Jumar team to learn more about residency opportunities.
If you'd like to receive the latest biotech news, events, and opportunities straight to your inbox - Subscribe to our newsletter.